Trust Co. of Vermont Raises Position in Becton Dickinson and Co (NYSE:BDX)

Trust Co. of Vermont lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 2.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,663 shares of the medical instruments supplier’s stock after buying an additional 1,476 shares during the period. Becton Dickinson and makes up 1.2% of Trust Co. of Vermont’s portfolio, making the stock its 18th biggest position. Trust Co. of Vermont’s holdings in Becton Dickinson and were worth $14,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC boosted its holdings in Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after purchasing an additional 842,590 shares during the last quarter. Ronna Sue Cohen boosted its holdings in Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after purchasing an additional 416,459 shares during the last quarter. Fundsmith LLP boosted its holdings in Becton Dickinson and by 0.9% in the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock valued at $941,772,000 after purchasing an additional 35,453 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Becton Dickinson and by 0.7% in the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock valued at $805,082,000 after purchasing an additional 23,645 shares during the last quarter. 84.85% of the stock is owned by institutional investors.

NYSE BDX traded up $3.65 on Tuesday, hitting $239.99. 1,866,062 shares of the stock traded hands, compared to its average volume of 845,774. The company has a 50-day moving average price of $250.82. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The stock has a market capitalization of $63.75 billion, a P/E ratio of 21.80, a P/E/G ratio of 1.84 and a beta of 1.11. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.06 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the prior year, the firm posted $2.91 earnings per share. Becton Dickinson and’s revenue for the quarter was up 1.7% compared to the same quarter last year. Research analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.

A number of brokerages recently commented on BDX. Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target for the company in a report on Monday, May 13th. Piper Jaffray Companies reissued an “overweight” rating and issued a $266.00 price target (down previously from $267.00) on shares of Becton Dickinson and in a report on Tuesday. KeyCorp reissued an “overweight” rating and issued a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Wells Fargo & Co cut their price objective on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research note on Monday, May 13th. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $264.27.

In other news, EVP Samrat S. Khichi sold 16,085 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the sale, the executive vice president now directly owns 12,608 shares in the company, valued at approximately $2,958,845.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the sale, the executive vice president now owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Insiders have sold a total of 21,154 shares of company stock worth $4,955,775 over the last quarter. Insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Golden Cross

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.